Design Therapeutics (DSGN) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Design Therapeutics (DSGN) over the past year, gaining 251.4% versus a gain of 63.6%. Design Therapeutics is the larger company by market cap ($729.1 million vs $689.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | NVCT |
|---|---|---|
| Share price | $11.65 | $21.12 |
| Market cap | $729.08M | $689.44M |
| 1-day change | +1.39% | +4.92% |
| YTD return | +24.20% | +179.74% |
| 1-year return | +63.62% | +251.41% |
| 5-year return | -18.25% | — |
| EPS (TTM) | $-1.18 | $-1.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $29.28 |
| 52-week low | $5.28 | $5.55 |
| Distance from 52-week high | -32.46% | -27.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +86.35% | +67.61% |
| Average volume | 596.56K | 214.31K |
| Shares outstanding | 62.58M | 32.64M |
| Employees | 55 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed DSGN by 187.8 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
DSGN vs NVCT FAQ
Which is bigger, Design Therapeutics or Nuvectis Pharma?
Design Therapeutics (DSGN) is larger, with a market capitalization of $729.08M compared with $689.44M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, DSGN or NVCT?
NVCT returned +251.41% over the past 12 months, compared with +63.62% for DSGN (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.